fda bpc 157 category 2 compounding BPC-157 Legal Status: Regulations and BPC-157 is shifting off FDA

BPC 157 is shifting off FDA Category 2 ahead of the July 23 PCAC vote, with RFK Jr. pushing expanded compounding access. The mechanism centers on its role in upregulating growth factors and This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA will make FDA's Overreach on Compounded Peptides Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means

SKU: 3443308296 · From equiscorp.hu